Becker's Spine Review

22 DEVICES & IMPLANTS Stryker, NuVasive in spine: 5 key comparisons By Laura Dyrda N uVasive and Stryker are among the top five companies leading the spine market and have continued to grow in the past 12 months. 1. 2019 spine revenue NuVasive: $1.17 billion, up 7 percent year over year Stryker: $1 billion, up 28 percent year over year 2. Quarterly spine revenue Stryker: $261 million (3.5 percent decrease) NuVasive: $259.9 million (5.4 percent de- crease) 3. Market share NuVasive: 13 percent Stryker: 12 percent *According to e Spine Market Group. 4. Leadership Spencer Stiles is the group president of ortho- pedics and spine at Stryker, a role he took on in August 2019. He oversees the company's joint replacement, trauma and extremities and spine businesses. He joined Stryker in 1999 and has spent four years as president of spine before becoming the group president of neurotechnology, instruments and spine. Chris Barry is the CEO of NuVasive, a role he took on in 2018 aer spending time as senior vice president and president of sur- gical innovations at Medtronic. While with Medtronic, he oversaw the $5.5 billion busi- ness unit for three years and led a team of 14,000 employees. 5. Big moves NuVasive: On June 18, NuVasive launched Reline 3D, a posterior fixation system for pediatric spinal deformities, in the U.S. It aims to launch the device in other countries next year. In May, the company also achieved two FDA clearances for two spine devices, the Modulus ALIF and Cohere TLIF-O, and launched the Modulus XLIF dual-sided plate. Stryker: In October 2019, Stryker acquired Mobius Imaging and Cardan Robotics to strengthen its presence in the orthopedics, spine and neurotechnology robotics space. It also acquired OrthoSpace in March 2019 for up to $220 million. n NuVasive spine robot faces further delays By Alan Condon D uring NuVasive's second-quarter earnings call, CEO Chris Barry said the timeline for its Pulse robotic system for spine surgery has been fur- ther delayed, according to Seeking Alpha. Four things to know: 1. The timeline for the Pulse system and its associated robotics application has been pushed back due to "soft- ware and hardware updates following beta testing, as well as the impact of COVID-19," Mr. Barry said. 2. NuVasive aims to finish testing and receive FDA clear- ances in the summer of 2021, rather than the previously communicated first half of 2021. The first-in-human use of the robotic system is expected to take place in 2022. 3. Mr. Barry reinforced that robotics is a key component of NuVasive's "imaging, navigation and automation strategy." He said that the company will have a better idea of the Pulse system's timeline over the next three to six months. 4. The Pulse system is an open imaging platform inte- grated with Siemens' 3D mobile C-arm, the Cios Spine. NuVasive expects it to compete with other robotic spine offerings on the market, including Medtronic's Mazor X, Globus Medical's ExcelsiusGPS and Zimmer Biomet's Rosa Spine. n Stryker's neurotechnology + spine sales drop 29.6% in Q2 By Alan Condon S econd-quarter neurotechnology and spine sales at Stryker decreased 29.6 percent to $546 million year over year. Six things to know: 1. Net sales in the second quarter declined 24.3 percent year over year to $2.8 billion. 2. Stryker's second-quarter orthopedics sales — including knees, hips, and trauma and other extremities — fell 29.9 per- cent, compared to the same period last year, to $894 million. 3. Knees sales suffered the biggest decline within the ortho- pedics line, decreasing 45.2 percent to $241 million year over year. 4. Most of Stryker's business units saw gradual recoveries in June, according to CEO Kevin Lobo. 5. Mr. Lobo said sales gathered momentum "through the quarter and into July" and are likely to continue to grow due to the resumption of elective surgeries. 6. Stryker will not be providing third quarter or full-year fi- nancial projections due to the uncertainty surrounding the COVID-19 pandemic. n

• Cover